Scientific Program

Conference Series Ltd invites all the participants across the globe to attend International Conference on Nuclear Medicine & Radiation Therapy Cologne, Germany.

Day 1 :

Keynote Forum

Carmen I Bigles

Coqui Pharma,USA

Keynote: Coqui-pharma solving the impending global shortage of molybdenum -99

Time : 09:00-09:30

OMICS International Nuclear Medicine 2016 International Conference Keynote Speaker Carmen I Bigles photo

Carmen I Bigles is CEO of Coquí Radio Pharmaceuticals, Corp. a company with the goal of establishing a medical radioisotope production facility in the U.S. As co-owner of Caribbean Radiation Oncology Center, she learned that many patients were being misdiagnosed due to a global shortage of 99Mo. She sought to learn more about the Mo-99 industry and ultimately decided to establish a domestic source of the isotope. She earned a Bachelor’s degree in Mathematics from Inter-American University in San Juan and subsequently her Master’s degrees in architecture and suburban and town planning from the University of Miami.


Coquí Radio Pharmaceuticals Corp. is a medical isotope company dedicated to the production of Molybdenum-99, which is used in 20 million procedures each year in the U.S. The Puerto Rican company is based in Coral Gables, Fla., with the mission to bring the foremost medical isotope production facility to the Western Hemisphere and to create a commercially scalable, reliable supply of medical diagnostic and therapeutic radioisotopes in the U.S. This presentation will give an overview of the medical isotope 99Mo and its uses in modern medicine and explore the potential effects of an impending global shortage as nuclear reactors around the world begin to go offline. Carmen will give a thorough overview of Coquí Pharma and its mission to solve the impending shortage crisis as well as explain the technology the firm will employ at its medical isotope production facility.

Keynote Forum

Joerg Traub

Surgic Eye GmbH, Germany

Keynote: 3D interventional nuclear medicine imaging and therapy monitoring

Time : 09:30-10:00

OMICS International Nuclear Medicine 2016 International Conference Keynote Speaker Joerg Traub photo

Joerg Traub has completed his PhD from TU Munich with highest distinction. After graduation, he was a co-founder of Surgic Eye GmbH. He is CEO and President of Surgic Eye, an innovator in the field of mobile nuclear imaging during therapy, for the past 8 years. He has published more than 50 peer-reviewed journals and full paper conference papers. He is co-inventor of more than 10 patents and has been serving as reviewer in several medical imaging and computer assisted surgery journals and conferences. rn


Radio-guided surgery is defined as any surgical procedure which utilizes a radiation detection device in a real-time fashion within the operating room for the identification of a radioisotope administered to a patient prior to the time of attempted detection and with the sole purpose of assisting in the successful performance of that surgical procedure. There is a wide application domain in the surgery room for sentinel lymph node marking, marking of primary tumors and also injection of radio-isotopes for selective internal radiation therapy.

Keynote Forum

Karl R Aigner

Medias Klinikum GmbH & Co KG, Germany

Keynote: High intra-arterial drug exposure for advanced head and neck cancer patients

Time : 10:00-10:30

OMICS International Nuclear Medicine 2016 International Conference Keynote Speaker Karl R Aigner photo

Karl R Aigner is Medical Director of the Department of Surgical Oncology in Medias Klinikum Burghausen (Bavaria)/Germany. He had his surgical training inrncardiovascular surgery at Friedrich-Alexander University in Erlangen. At Justus-Liebig University Giessen, he specialized in surgical oncology, focusing on vascularrntechniques of drug delivery such as Implantofix and Jet Port Catheters, and in 1981 first performed a technique of isolated perfusion of the liver with heart-lungrnmachine in man. Furtheron, he developed various techniques of segmental vascular isolation of body segments and organs, and the stopflow technique withrnadequately designed catheters. In 1982, together with Prof. Stephens from Sydney, he initiated the biannual International Congress of Regional Cancer Treatmentrn(ICRCT) and from 1987 to 1991 was President of the International Society for Regional Cancer Therapy. From 1985 to 1998, he was Managing Editor of thernInternational Journal Regional Cancer Treatment. He is author of numerous publications and book chapters, lectured and performed teaching operations onrnvascular perfusion techniques and oncological surgery in Europe the United States and Asia.


Introduction: Standard treatment for tumors of the head and neck are radiochemotherapy and surgery. In far, advanced orrnrecurrent cases surgery may be impossible or mutilating and side-effects from irradiation in terms of nerve damage and mouthrndryness are not reversible. In order to avoid toxicity and permanent tissue and nerve damage, we performed a study withrncarotid artery infusion and chemofiltration for simultaneous detoxification.rnMaterial & Methods: Carotid artery infusion was accomplished either via angiographic catheters in Seldinger’s technique orrnby means of end-to-side implantation of Jet Port Allround catheters into one or two carotid arteries respectively. Intra-arterialrninfusion time of a three-drug combination consisting of Cisplatin, Adriamycin and Mitomycin in 7 to 10 minutes short termrninfusions generates local drug levels eighty- to hundred-fold higher than during systemic chemotherapy. A total of 26 patientsrnwere included in the study, 18 patients in clinical stage IV, 5 in stage III and 3 in stage II respectively. For follow-up control andrndetermination of adverse effects, blood work (hemoglobine, white blood count, platelets, cardiac, kidney and liver enzymes),rnperformance scale, pain score, survival rate, hospitalization and side-effects were noted.rnResults: Five out of 26 patients died from their disease, one after a car accident. The average follow-up time was 45 months.rnStage IV patients who died had an average survival time of 11 months after onset of therapy. Surviving patients have notrnreached the median survival rate yet and are still alive on an average of 43 months after onset of therapy. There was no relevantrnhematologic toxicity (WHO Grade I – II) and there was no neurotoxicity. Vital parameters such as the ability to speak orrnto swallow usually improved after the second or third out of five treatment cycles. The major surgical complication was therndissection of the carotid artery in three cases.rnConclusion: Regional chemotherapy for advanced cancers of the head and neck area in terms of intra-arterial infusion withrnchemofiltration induces rapid tumor shrinkage without relevant toxicity and substantially improves quality of life.